Clinical Neuropathology · 2013 · 53 citations · 24 references
MedicineNeurologyOncologyEpigeneticsMolecular OncologyNeuro-oncologyBrain TumorsCancer BiomarkersDna MethylationDna Methylation ProfilingGlioblastomaNext-generation Sequencing In OncologyBisulfite SequencingGlioblastoma Clinical TrialsGlioblastoma PrognosisGlioblastoma TrialsMethylation BiomarkersPhase Iii Clinical TrialsPhase Iii Oncology TrialsPromoter Methylation
Testing of the MGMT promoter methylation status in glioblastoma is relevant for clinical decision making and research applications. Two recent and independent phase III therapy trials confirmed a prognostic and predictive value of the MGMT promoter methylation status in elderly glioblastoma patients. Several methods for MGMT promoter methylation testing have been proposed, but seem to be of limited test reliability. Therefore, and also due to feasibility reasons, translation of MGMT methylation testing into routine use has been protracted so far. Pyrosequencing after prior DNA bisulfite modification has emerged as a reliable, accurate, fast and easy-to-use method for MGMT promoter methylation testing in tumor tissues (including formalin fixed and paraffin-embedded samples). We performed an intra- and inter-laboratory ring trial which demonstrates a high analytical performance of this technique. Thus, pyrosequencing- based assessment of MGMT promoter methylation status in glioblastoma meets the criteria of high analytical test performance and can be recommended for clinical application, provided that strict quality control is performed. Our article summarizes clinical indications, practical instructions and open issues for MGMT promoter methylation testing in glioblastoma using pyrosequencing.
24
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Roger Stupp, Warren Mason, Martin J. van den Bent et al. · New England Journal of Medicine · 2005 · 21.6K citations · Full text
Roger Stupp, Monika E. Hegi, Warren Mason et al. · The Lancet Oncology · 2009 · 7.8K citations
<i>MGMT</i> Gene Silencing and Benefit from Temozolomide in Glioblastoma
Monika E. Hegi, Annie‐Claire Diserens, Thierry Gorlia et al. · New England Journal of Medicine · 2005 · 7.3K citations · Full text
A Sequencing Method Based on Real-Time Pyrophosphate
Mostafa Ronaghi, Mathias Uhlén, Pål Nyrén · Science · 1998 · 1.6K citations